We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current STRO market cap is 248.35M. The company's latest EPS is USD -1.3029 and P/E is -2.22.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.41M | 16.92M | 113.72M | 13.01M | 25.71M |
| Operating Income | -46.18M | -44.01M | 43.15M | -56.59M | -48.69M |
| Net Income | -38.52M | -49.28M | 31.07M | -58.21M | -48.02M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.74M | 42.72M | 61.88M | 67.77M | 153.73M |
| Operating Income | -55.47M | -71.06M | -98.52M | -128.94M | -89.28M |
| Net Income | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 464.9M | 431.73M | 470.74M | 403.4M | 489.04M |
| Total Liabilities | 310.18M | 319.39M | 321.09M | 305.38M | 336.87M |
| Total Equity | 154.72M | 112.35M | 149.65M | 98.02M | 152.18M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 156.37M | 394.11M | 341.41M | 406.94M | 470.74M |
| Total Liabilities | 58.58M | 62.06M | 88.84M | 189.9M | 321.09M |
| Total Equity | 97.79M | 332.05M | 252.56M | 217.05M | 149.65M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -92.19M | -125.69M | -111.62M | -64.74M | -55.29M |
| Investing | 133.61M | 19.59M | -3.92M | 64.11M | -16.27M |
| Financing | 146.42M | 140.68M | 137.55M | -3.43M | 93.06M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -65.02M | -67.8M | -81.68M | 3.55M | -111.62M |
| Investing | -51.13M | 604k | -97.32M | -35.02M | -3.92M |
| Financing | -4.18M | 269.25M | 3.26M | 48.31M | 137.55M |
| Market Cap | 248.35M |
| Price to Earnings Ratio | -2.22 |
| Price to Sales Ratio | 1.54 |
| Price to Cash Ratio | 3.42 |
| Price to Book Ratio | 1.58 |
| Dividend Yield | - |
| Shares Outstanding | 81.96M |
| Average Volume (1 week) | 524.74k |
| Average Volume (1 Month) | 523.65k |
| 52 Week Change | 29.49% |
| 52 Week High | 6.13 |
| 52 Week Low | 2.13 |
| Spread (Intraday) | 0.5 (14.71%) |
| Company Name | Sutro Biopharma Inc |
| Address |
310 utah ave., suite 150 south san francisco, california 94080 |
| Website | https://www.sutrobio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
